# Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence

> **NCT04797000** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 36 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Eltrombopag
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04797000
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-25
- **Primary completion:** 2025-04-26
- **Final completion:** 2026-12-09
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04797000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04797000, "Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04797000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*